A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.